NLRP3 and depressive symptom measurement: Furthermore, the inhibition of NLRP3 inflammasome may have the potential to reduce the risk of depression after AMI, particularly within the subgroup exhibiting elevated baseline levels of NLRP3, leading to improvements in cardiovascular outcomes.